- Check Our Services
Amyloidosis Registries Africa
Details
READING TIME
3 min
CATEGORY
Blog
AUTHOR
John Dawod
TOPIC
Amyloidosis Africa
Why Africa Needs Its Own Amyloidosis Research and Registries
Amyloidosis is a complex and often underrecognized disease that affects multiple organs, including the heart, kidneys, nervous system, and gastrointestinal tract. While awareness of amyloidosis has improved significantly in Europe and North America, the disease remains poorly understood and frequently missed across many African healthcare systems. One of the most important steps toward improving diagnosis, treatment, and patient outcomes in Africa is the development of dedicated amyloidosis research programs and national or regional disease registries.
Without African research and registries, thousands of patients may remain undiagnosed or misdiagnosed. Establishing robust data systems will allow clinicians and researchers to better understand the true burden of amyloidosis on the continent and guide strategies for early detection and treatment.
NEW WEBSITE
LATEST EVENT
The Hidden Burden of Amyloidosis in Africa
Amyloidosis is often described as a rare disease, but many experts now believe it is rarely diagnosed rather than truly rare. In particular, cardiac amyloidosis, including transthyretin amyloid cardiomyopathy (ATTR-CM), is increasingly recognized as an important cause of heart failure worldwide.
Studies in Europe and the United States suggest that ATTR-CM may account for a significant proportion of heart failure cases in older adults. However, in Africa, the true prevalence of the disease is largely unknown due to the absence of systematic screening programs and registries.
Several factors contribute to this knowledge gap:
Limited awareness among healthcare providers
Restricted access to advanced diagnostic tools such as nuclear scintigraphy or genetic testing
Misclassification of amyloidosis as other cardiac or renal diseases
Lack of epidemiological research focusing on African populations
Because of these challenges, many patients are diagnosed very late, when the disease has already caused severe organ damage.
Why Local Research Is Essential
Most of the current knowledge about amyloidosis comes from studies conducted in North America, Europe, and parts of Asia. While these studies have significantly advanced medical understanding, their findings may not fully reflect the realities of African populations.
Local research is essential for several reasons.
Understanding Population Differences
Genetic and environmental factors can influence how diseases develop and progress. Certain hereditary forms of transthyretin amyloidosis (hATTR) are linked to specific gene mutations that may vary between populations.
African populations may have unique genetic variants that influence disease prevalence, clinical presentation, or response to therapy. Without local research, these differences remain poorly understood.
Improving Diagnostic Pathways
Many African healthcare systems face significant resource constraints. Diagnostic algorithms that rely heavily on advanced imaging or specialized laboratory tests may not always be feasible in low-resource settings.
Research conducted in African hospitals and clinics can help develop adapted diagnostic pathways that use available tools effectively while still enabling earlier detection of the disease.
Informing Public Health Policy
Governments and health ministries rely on epidemiological data to prioritize diseases and allocate resources. If amyloidosis remains invisible in national health data, it will rarely receive attention from policymakers.
Local research provides the evidence needed to advocate for better diagnostic services, training programs, and treatment access.
The Critical Role of Amyloidosis Registries
A disease registry is a structured system that collects standardized information about patients diagnosed with a specific condition. Registries play a crucial role in modern medicine because they allow researchers and clinicians to track disease patterns, evaluate treatments, and identify opportunities for improvement in care.
For amyloidosis in Africa, registries could transform the landscape of research and clinical practice.
Mapping the True Prevalence
One of the biggest unanswered questions is how common amyloidosis actually is in African populations. Registries allow healthcare systems to track diagnosed cases and analyze patterns across regions and healthcare facilities.
Over time, these data can reveal whether certain populations or regions are disproportionately affected and guide targeted awareness campaigns.
Understanding Clinical Presentation
Amyloidosis can present with a wide range of symptoms, including heart failure, neuropathy, kidney dysfunction, or gastrointestinal problems. Because these symptoms overlap with many other conditions, the disease is frequently overlooked.
Registry data can help clinicians identify common red flag symptoms in African patients and improve diagnostic recognition.
Evaluating Treatment Outcomes
New therapies for amyloidosis have emerged in recent years, particularly for transthyretin amyloidosis. However, access to these treatments remains limited in many parts of Africa.
Registries enable researchers to track treatment outcomes, assess effectiveness, and generate real-world evidence that can support expanded access to therapy.
Supporting Clinical Trials
Global clinical trials often struggle to recruit patients from Africa due to the lack of structured data systems and disease registries. This leads to underrepresentation of African populations in research.
By establishing national or regional amyloidosis registries, African institutions can become more attractive partners for international research collaborations and clinical trials.
Strengthening Collaboration Across Africa
Amyloidosis is a complex disease that requires collaboration between multiple specialties, including cardiology, nephrology, neurology, genetics, and pathology. Building strong networks among clinicians and researchers is therefore essential.
Registries can serve as the backbone of these collaborations by providing shared data platforms that connect hospitals and research institutions across countries.
Pan-African initiatives can further accelerate progress by:
Facilitating multicenter studies
Sharing best practices in diagnosis and management
Promoting training and education for healthcare professionals
Advocating for improved access to diagnostics and treatment
Such collaboration ensures that knowledge gained in one country can benefit patients across the entire continent.
The Role of Awareness and Education
Even the best registries cannot succeed without awareness among healthcare providers. Education programs for physicians, clinical officers, nurses, and other healthcare professionals are essential for improving recognition of the disease.
Training initiatives can focus on identifying early warning signs such as:
Unexplained heart failure with preserved ejection fraction
Thickened heart walls on echocardiography
Peripheral neuropathy without a clear cause
Proteinuria or kidney dysfunction with unclear etiology
By increasing awareness of these red flags, healthcare providers can refer patients for further evaluation earlier in the disease course.
Building the Future of Amyloidosis Research in Africa
The future of amyloidosis care in Africa depends on building strong foundations for research, data collection, and collaboration. Establishing registries and expanding research capacity will allow African clinicians and scientists to generate their own evidence and contribute meaningfully to global understanding of the disease.
Organizations, research groups, and professional societies across the continent are beginning to recognize the importance of this work. Through coordinated efforts, Africa can develop a sustainable ecosystem for amyloidosis research that benefits both local patients and the global scientific community.
A Call to Action
Addressing the challenges of amyloidosis in Africa requires commitment from multiple stakeholders, including clinicians, researchers, policymakers, patient advocates, and international partners.
Key priorities include:
Establishing national and regional amyloidosis registries
Expanding clinician education and awareness programs
Improving access to diagnostic tools and genetic testing
Encouraging multicenter research collaborations
Ensuring African representation in global clinical trials
By investing in research and registries today, Africa can transform the future of amyloidosis diagnosis and care.
Initiatives that bring together clinicians, researchers, and healthcare organizations across the continent are an important step toward this goal. With the right infrastructure and collaboration, Africa has the potential to become a significant contributor to global amyloidosis research while improving outcomes for patients who have long remained invisible.
Causes
Pan-African Research Collaboration
Quality Improvement & Impact
Documents
We advance cardiac amyloidosis care across Africa through collaboration, training, and research. Join us to change the future of heart health and empower local clinicians with knowledge and tools.
- Support cardiac care in Africa
- Give what you can to help
- Join our research network!
- Follow updates and news
